NC762
NC762 is a humanized IgG1κ monoclonal antibody that targets human B7-H4 (B7 homolog 4) . NC762 has enhanced binding to CD16a (FcγRIIIa) after being Fc engineered with three point mutations (S239D/A330L/I332E; DLE) and demonstrate increased antibody-dependent cellular cytotoxicity (ADCC) activity. NC762 inhibits tumor growth in vivo through binding to tumor-expressing B7-H4. NC762 can be studies in research on cancer such as advanced or metastatic solid tumors[1].
Product Specifications
UNSPSC
12352203
Target
TNF Receptor; Transmembrane Glycoprotein
Related Pathways
Apoptosis; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
References & Citations
[1]Myint, Han, et al. "748 A phase 1/2, open-label, dose-escalation, safety and tolerability study of NC762 in subjects with advanced or metastatic solid tumors." (2022) .|[2]Kristina Archer, et al. Abstract 3193: Development and functional characterization of NC762, a novel therapeutic antibody targeting B7-H4, for the treatment of malignancies. Cancer Res 1 July 2021; 81 (13_Supplement) : 3193.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
